История вопроса о роли биопсии костного мозга в системе стадирования классической лимфомы Ходжкина и современный взгляд в эру ПЭТ-КТ (обзор литературы)

ОБЗОРЫ , ,

А.А. Даниленко, Н.А. Фалалеева, С.В. Шахтарина

Медицинский радиологический научный центр им. А.Ф. Цыба — филиал ФГБУ «НМИЦ радиологии» Минздрава России, ул. Королева, д. 4, Обнинск, Калужская область, Российская Федерация, 249036

Для переписки: Анатолий Александрович Даниленко, д-р мед. наук, ул. Королева, д. 4, Обнинск, Российская Федерация, 249036; тел.: +7(909)250-18-10; e-mail: danilenkoanatol@mail.ru

Для цитирования: Даниленко А.А., Фалалеева Н.А., Шахтарина С.В. История вопроса о роли биопсии костного мозга в системе стадирования классической лимфомы Ходжкина и современный взгляд в эру ПЭТ-КТ (обзор литературы). Клиническая онкогематология. 2023;16(4):351–60.

DOI: 10.21320/2500-2139-2023-16-4-351-360

РЕФЕРАТ

Стадирование лимфомы Ходжкина представляет собой основу для выбора оптимальной программы лечения. Неотъемлемой частью стадирования в течение долгого времени оставалась оценка костного мозга. Исследование вовлеченности костного мозга в опухолевый процесс включает в себя применение методов лучевой диагностики и морфологического исследования его образцов, получаемых методом трепанобиопсии. На протяжении пяти десятилетий использования трепанобиопсии отношение онкологов и гематологов к этой инвазивной и болезненной манипуляции остается противоречивым — от полного отрицания до необходимости проведения ее каждому или большинству пациентов. Данный обзор посвящен истории вопроса и целесообразности применения трепанобиопсии у больных классической лимфомой Ходжкина.

Ключевые слова: лимфома Ходжкина, костный мозг, трепанобиопсия.

Получено: 26 марта 2023 г.

Принято в печать: 2 сентября 2023 г.

Читать статью в PDF

Статистика Plumx русский

ЛИТЕРАТУРА

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi: 10.3322/caac.21708.
  2. Sasse S, Brockelmann PJ, Goergen H, et al. Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. J Clin Oncol. 2017;35:1999–2007. doi: 10.1200/JCO.2016.70.9410.
  3. Subramanian G, Basu D, Badhe B, Dutta TK. Role of bone marrow trephine biopsy in the diagnosis of marrow involvement in Hodgkin’s disease. Indian J Pathol Microbiol. 2007;50(3):640–3.
  4. Weiler-Sagie M, Kagna O, Dann EJ, et al. Characterizing bone marrow involvement in Hodgkin’s lymphoma by FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2014;41(6):1133–40. doi: 10.1007/s00259-014-2706-x
  5. Ghedini G. Per la patogenesi e per la diagnosi delle malattie del sangue e degli organi emopoietici, punture esplorativa del midollo osseo. Clinic Medica Italiana. 1908;47:724–36.
  6. Seyfarth C. Eine einfache Methode zur diagnostichen Entnahme von Knochenmark beim Lebenden. Arch fur Schiffs-und Tropen-Hygiene, Pathologie und Therapie exotischer Krankheiten. 1922;26:337–41.
  7. Arinkin MI. Die Intravitale Untersuchungsmethodik des Knochenmarks. Folia Haematologica. 1929;38:233–40.
  8. Arjeff MJ. Zur Methodik der Diagnostischen Punktion des Brustbeines. Folia Haematologica. 1931;45:55.
  9. Воробьев А.И. И.А. Кассирский и его вклад в медицину. М.: Медицина, 1988.
    [Vorob’ev AI. I.A. Kassirskii i ego vklad v meditsinu. (I.A. Kassirskii and his contribution to medicine.) Moscow: Meditsina; 1988. (In Russ)]
  10. Rubinstein MA. The technic and diagnostic value of aspiration of bone marrow from the iliac crest. Ann Intern Med. 1950;32:1905–8.
  11. Bierman HR. Bone marrow aspiration of the posterior iliac crest, an additional safe site. California Med. 1952;77:138–9.
  12. Jamshidi K, Swaim WR. Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med. 1971;77(2):335–42.
  13. Hernandez-Garcia MT, Hernandez-Nieto L, Perez-Gonzalez E, Brito-Barroso ML. Bone marrow trephine biopsy: anterior superior iliac spine versus posterior superior iliac spine. Clin Lab Haematol. 1993;15(1):15–9. doi: 10.1111/j.1365-2257.1993.tb00117.x.
  14. Tomasian A, Jennings JW. Bone marrow aspiration and biopsy: techniques and practice implications. Skeletal Radiol. 2022;51(1):81–8. doi: 10.1007/s00256-021-03882-w.
  15. Draganski E, Deason T, Craig FE. Bone Marrow Aspiration and Biopsy Performed by RNs: A Review of Clinical Practice. Am J Nurs. 2019;119(9):47–53. doi: 10.1097/01.NAJ.0000580260.18537.ca.
  16. Криволапов Ю.А. Биопсия костного мозга: научно-практическое издание. М.: Практическая медицина, 2014. 528 с.
    [Krivolapov YuA. Biopsiya kostnogo mozga: nauchno-prakticheskoe izdanie. (Bone marrow biopsy: research and practice edition.) Moscow: Prakticheskaya meditsina Publ.; 2014. 528 p. (In Russ)]
  17. Howell SJ, Grey M, Changet L, et al. The value of bone marrow examination in the staging of Hodgkin’s lymphoma: a review of 955 cases seen in a regional cancer centre. Br J Haematol. 2002;119(2):408–11. doi: 10.1046/j.1365-2141.2002.03842.x.
  18. Fend F, Kremer M. Diagnosis and classification of malignant lymphoma and related entities in the bone marrow trephine biopsy. Pathobiology. 2007;74(2):133–43. doi: 10.1159/000101712.
  19. Brunning RD, Bloomfield CD, McKenna RW, Peterson LA. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;82(3):365–6. doi: 10.7326/0003-4819-82-3-365.
  20. Levis A, Pietrasanta D, Godio L, et al. A large-scale study of bone marrow involvement in patients with Hodgkin’s lymphoma. Clin Lymphoma. 2004;5(1):50–5. doi: 10.3816/clm.2004.n.010.
  21. Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer. 2002;94(5):1522–31. doi: 10.1002/cncr.10364.
  22. Menon NC, Buchanan JG. Bilateral trephine bone marrow biopsies in Hodgkin’s and non-Hodgkin’s lymphoma. Pathology. 1979;11(1):53–7. doi: 10.3109/00313027909063538.
  23. Almeida J, Garcia-Marcos MA, Vallejo C, et al. Results of a series of 104 consecutive bilateral bone marrow biopsy specimens in lymphoproliferative disorders. Sangre (Barc). 1995;40(5):365–8.
  24. Luoni M, Fava S, Declich PJ. Bone marrow biopsy for staging Hodgkin’s lymphoma: the value of bilateral or unilateral trephine biopsy. J Clin Oncol. 1996;14(2):682–3. doi: 10.1200/JCO.1996.14.2.682.
  25. Kluin-Nelemans HC, Noordijk EM. Staging of patients with Hodgkin’s disease: what should be done? Leukemia. 1990;4(2):132–5.
  26. Bartl R, Frisch B, Burkhardt R, et al. Assessment of bone marrow histology in the malignant lymphomas (non-Hodgkin’s): correlation with clinical factors for diagnosis, prognosis, classification and staging. Br J Haematol. 1982;51(4):511–30. doi: 10.1111/j.1365-2141.1982.tb02815.x.
  27. Straus DJ, Gaynor JJ, Myers J, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8(7):1173–86. doi: 10.1200/JCO.1990.8.7.1173.
  28. Даниленко А.А. Поражение костного мозга у больных лимфогранулематозом (диагностика, клинические формы, патогенез): Автореф. дис. … канд. мед. наук. М., 2004.
    [Danilenko AA. Porazhenie kostnogo mozga u bolnykh limfogranulematozom (diagnostika, klinicheskie formy, patogenez). (Bone marrow lesions in Hodgkin lymphoma patients (diagnosis, clinical presentations, pathogenesis). [dissertation] Moscow; 2004. (In Russ)]
  29. Kaplan HS. Contiguity and progression in Hodgkin’s disease. Cancer Res. 1971;31(11):1811–3.
  30. Macintyre EA, Vaughan Hudson B, Linch DC, et al. The value of staging bone marrow trephine biopsy in Hodgkin’s disease. Eur J Haematol. 1987;39(1):66–70. doi: 10.1111/j.1600-0609.1987.tb00166.x.
  31. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res. 1971;31(11):1860–1.
  32. Hines-Thomas MR, Howard SC, Hudson MM, et al. Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin’s lymphoma. Haematologica. 2010;95(10):1691–6. doi: 10.3324/haematol.2010.025072.
  33. Ellis ME, Diehl LF, Granger E, Elson E. Trephine needle bone marrow biopsy in the initial staging of Hodgkin disease: sensitivity and specificity of the Ann Arbor staging procedure criteria. Am J Hematol. 1989;30(3):115–20. doi: 10.1002/ajh.2830300302.25.
  34. Doll DC, Ringenberg QS, Anderson SP, et al. Bone marrow biopsy in the initial staging of Hodgkin’s disease. Med Pediatr Oncol. 1989;17(1):1–5. doi: 10.1002/mpo. 2950170102.
  35. Munker R, Hasenclever D, Brosteanu O, et al. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 1995;13(2):403–9. doi: 10.1200/JCO.1995.13.2.403.
  36. Howard MR, Taylor PR, Lucraft HH, et al. Bone marrow examination in newly diagnosed Hodgkin’s disease: current practice in the United Kingdom. Br J Cancer. 1995;71(1):210–2. doi: 10.1038/bjc.1995.43.
  37. MacCormick R, Covert A, Gross M. Primary bony involvement in Hodgkin’s disease. CMAJ. 1989;140(9):1059–60.
  38. Borg MF, Chowdhury AD, Bhoopal S, Benjamin CS. Bone involvement in Hodgkin’s disease. Australas Radiol. 1993;37(1):63–6. doi: 10.1111/j.1440-1673.1993.tb 00011.x.
  39. Ostrowski ML, Inwards CY, Strickler JG. Osseous Hodgkin disease. Cancer. 1999;85(5):1166–78. doi: 10.1002/(sici)1097-0142(19990301)85:5<1166::aid-cncr22>3.0.co;2-v.
  40. Langley CR, Garrett SJ, Urand J, et al. Primary multifocal osseous Hodgkin’s lymphoma. World J Surg Oncol. 2008;6:34. doi: 10.1186/1477-7819-6-34.
  41. Anderson KC, Kaplan WD, Leonard RC, et al. Role of 99mTc methylene diphosphonate bone imaging in the management of lymphoma. Cancer Treat Rep. 1985;69(12):1347–51.
  42. Ferrant A, Rodhain J, Michaux JL, et al. Detection of skeletal involvement in Hodgkin’s disease: A comparison of radiography, bone scanning, and bone marrow biopsy in 38 patients. Cancer. 1975;35(5):1346–53. doi: 10.1002/1097-0142(197505)35:5<1346::aid-cncr2820350516>3.0.co;2-i.
  43. Daffner RH, Lupetin AR, Dash N, et al. MRI in the detection of malignant infiltration of bone marrow. Am J Roentgenol. 1986;146(2):353–8. doi: 10.2214/ajr.146.2.353.
  44. Vogler JB, Murphy WA. Bone marrow imaging. Radiology. 1988;168(3):679–93. doi: 10.1148/radiology.168.3.3043546.
  45. Guckel F, Semmler W, Dohner H, et al. NMR tomographic imaging of bone marrow infiltrates in malignant lymphoma. Rofo. 1989;150(1):26–31. doi: 10.1055/s-2008-1046968.
  46. Chiarilli MG, Delli Pizzi A, Mastrodicasa D, et al. Bone marrow magnetic resonance imaging: physiologic and pathologic findings that radiologist should know. Radiol Med. 2021;126(2):264–76. doi: 10.1007/s11547-020-01239-2.
  47. Hoane BR, Shields AF, Porter BA, Shulman HM. Detection of lymphomatous bone marrow involvement with magnetic resonance imaging. Blood. 1991;78(3):728–38.
  48. Dohner H, Guckel F, Knauf W, et al. Magnetic resonance imaging of bone marrow in lymphoproliferative disorders: correlation with bone marrow biopsy. Br J Haematol. 1989;73(1):12–7. doi: 10.1111/j.1365-2141.1989.tb00211.x.
  49. Linden A, Zankovich R, Theissen P, et al. Malignant lymphoma: bone marrow imaging versus biopsy. Radiology. 1989;173(2):335–9. doi: 10.1148/radiology.173.2.2678249.
  50. Shields AF, Porter BA, Churchley S, et al. The detection of bone marrow involvement by lymphoma using magnetic resonance imaging. J Clin Oncol. 1987;5(2):225–30. doi: 10.1200/JCO.1987.5.2.225.
  51. Tardivon AA, Munck JN, Shapeero LG. Can clinical data help to screen patients with lymphoma for MR imaging of bone marrow? Ann Oncol. 1995;6(8):795–800. doi: 10.1093/oxfordjournals.annonc.a059318.
  52. Skillings JR, Bramwell V, Nicholson RL, et al. A prospective study of magnetic resonance imaging in lymphoma staging. Cancer. 1991;67(7):1838–43. doi: 10.1002/1097-0142(19910401)67:7<1838::aid-cncr2820670704>3.0.co;2-o.
  53. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S42–S55. doi: 10.1007/s00259-003-1159-4.
  54. Kniseley RM, Andrews GA, Edwards CL, Hayes RL. Bone-marrow and skeletal scanning. Radiol Clin North Am. 1969;7(2):265–80.
  55. Lilien DL, Berger HG, Anderson DP, Bennett LR. 111 In-chloride: a new agent for bone marrow imaging. J Nucl Med. 1973;14(3):184–6.
  56. Krause T, Eisenmann N, Reinhardt M, et al. Bone marrow scintigraphy using technetium-99m antigranulocyte antibody in malignant lymphomas. Ann Oncol. 1999;10(1):79–85. doi: 10.1023/a:1008356910239.
  57. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630–6. doi: 10.1200/JCO.1989.7.11.1630.
  58. Dahlbom M, Hoffman EJ, Hoh CK, et al. Whole-body positron emission tomography: Part I. Methods and performance characteristics. J Nucl Med. 1992;33(6):1191–9.
  59. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-[18F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1993;17(4):582–9. doi: 10.1097/00004728-199307000-00012.
  60. Basu S, Hess S, Nielsen Braad PE, et al. The Basic Principles of FDG-PET/CT Imaging. PET Clin. 2014;9(4):355–70. doi: 10.1016/j.cpet.2014.07.006.
  61. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28(3):288–92.
  62. Newman JS, Francis IR, Kaminski MR, Wahl RL. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology. 1994;190(1):111–6. doi: 10.1148/radiology.190.1.8259386.
  63. Hoh CK, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin’s disease and lymphoma. J Nucl Med. 1997;38(3):343–8.
  64. Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91(5):889–99.
  65. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging – do we need contrast-enhanced CT? Radiology. 2004;232(3):823–9. doi: 10.1148/radiol.2323030985.
  66. Hoh CK, Hawkins RA, Dahlbom M, et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr. 1993;17(1):34–41. doi: 10.1097/00004728-199301000-00005.
  67. Bangerter M, Moog F, Buchmann I, et al. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Ann Oncol. 1998;9(10):1117–22. doi: 10.1023/a:1008486928190.
  68. Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009;50(8):1257–60. doi: 10.1080/10428190903040048.
  69. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048–58. doi: 10.1200/JCO.2013.53.5229.
  70. Moulin-Romsee G, Hindie E, Cuenca X, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37(6):1095–105. doi: 10.1007/s00259-009-1377-5.
  71. Adams HJ, Kwee TC, de Keizer B, et al. Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? Ann Oncol. 2014;25(5):921–7. doi: 10.1093/annonc/mdt533.
  72. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68. doi: 10.1200/JCO.2013.54.8800.
  73. Puccini B, Nassi L, Minoia C, et al. Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography. Ann Hematol. 2017;96(7):1147–53. doi: 10.1007/s00277-017-2996-8.
  74. Voltin CA, Goergen H, Baues C, et al. Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. Ann Oncol. 2018;29(9):1926–31. doi: 10.1093/annonc/mdy250.
  75. Gallamini A. Hodgkin lymphoma staging 50 years later: no more knives or needles! Ann Oncol. 2018;29(9):1892–3. doi: 10.1093/annonc/mdy262.
  76. Gaudio F, Pedote P, Niccoli Asabella A, et al. Bone Involvement in Hodgkin’s Lymphoma: Clinical Features and Outcome. Acta Haematol. 2018;140(3):178–82. doi: 10.1159/000490489.
  77. Kwee TC, de Klerk JMH, Nix M, et al. Benign Bone Conditions That May Be FDG-avid and Mimic Malignancy. Semin Nucl Med. 2017;47(4):322–51. doi: 10.1053/j.semnuclmed. 2017.02.004.